XM nie świadczy usług obywatelom Stanów Zjednoczonych.
R
R

RECSilicon


Wiadomości

Italy - Factors to watch on July 9

Italy - Factors to watch on July 9 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . DEBT Treasury to sell up to 8.5 billion euros in bonds at July 11 auction .
A
A
B
E
I
L
P
R
A
I
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Liberty Global, Crest Nicholson, NCR Voyix and Baxter International July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2 000 GMT on Friday: * * Private equity firm Carlyle Group is in exclusive talks to acquire Baxter International's BAX.N kidney care spinoff Vantive for more than $4 billion, including debt, a person familiar with the matter told Reuters.
B
B
B
C
G
H
R
S
T
U
B
T

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Thyssenkrupp, Dompe Farmaceutici, Crest Nicholson Updates: BBVA July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday: ** Thyssenkrupp TKGA.DE , Salzgitter SZGG.DE and France's Vallourec VLLP.PA are reviewing a sale of their steel joint venture HKM after they were approached by a potential buyer, Germany's largest steelmaker said.
B
B
C
G
H
R
S
T
U
B
T

Italy's Dompe not interested in possible deal with rival drugmaker Recordati

Italy's Dompe not interested in possible deal with rival drugmaker Recordati MILAN, July 5 (Reuters) - Italy's Dompe Farmaceutici is not interested in rival drugmaker Recordati RECI.MI , the biopharmaceutical group's chief executive and chairman said on Friday. "We had looked at it... it is a large company ...we are not on the file," Sergio Dompe told Reuter.
R

Recordati shares rise as investors reportedly circle CVC stake

Recordati shares rise as investors reportedly circle CVC stake MILAN, June 18 (Reuters) - Shares in Italian drugmaker Recordati RECI.MI rose almost 3% on Tuesday, boosted by a report that investment funds KKR KKR.N and TPG TPG.O had expressed preliminary interest in buying a stake in the company. Speculation about the future of Recordati has increased after majority shareholder CVC Capital Partners CVC.AS hired investment banks JP Morgan and Goldman Sachs to explore options for the pharmaceutica
R

Recordati rises after media report on KKR, TPG interest

BUZZ-Recordati rises after media report on KKR, TPG interest ** Shares in Recordati RECI.MI rise as much as 3% after Bloomberg News reported that KKR KKR.N and TPG TPG.O expressed interest in buying a stake in the Italian drugmaker ** The two investment funds, pharma company Angelini Pharma and an Abu Dhabi sovereign fund are among suitors for part or all of the 51.8% stake owned by CVC Capital Partners, Bloomberg News said on Monday, citing people familiar with the matter ** CVC declined to com
R

Italy - Factors to watch on June 18

Italy - Factors to watch on June 18 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . COMPANIES UNICREDIT CRDI.MI The bank said on Monday it was "well above " MREL requirements set by the Single Resolution Board (SRB) and the Bank of Italy, with MREL eligible liabilities equal to 32.8% of risk-weighe
A
E
I
I
L
L
M
R
U
A
B
B
F
I
U

KKR, TPG express interest in Italian drugmaker Recordati - Bloomberg News

MEDIA-KKR, TPG express interest in Italian drugmaker Recordati - Bloomberg News -- Source link: https://tinyurl.com/28c759fu -- Note: Reuters has not verified this story and does not vouch for its accuracy
R

Eiffage, Quilter, Ricardo

EUROPE RESEARCH ROUNDUP-Eiffage, Quilter, Ricardo June 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Eiffage, Quilter and Ricardo, on Monday. HIGHLIGHTS * Acciona Energia ANE.MC : Morgan Stanley raises to equalweight from underweight * Eiffage FOUG.PA : Goldman Sachs raises to buy from neutral * Quilter Plc QLT.L : JP Morgan raises to overweight from neutral * Ricardo Plc RCDO.L : Berenberg raises to buy from hold * St.
B
C
C
E
H
H
I
I
J
P
P
R
S
V
D
L
N

Carlsberg, Danske Bank, Teleperformance

EUROPE RESEARCH ROUNDUP- Carlsberg, Danske Bank, Teleperformance May 10 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Carlsberg, Danske Bank and Teleperformance, on Friday. HIGHLIGHTS * Carlsberg A/S CARLB.CO : HSBC raises target price to DKK 1040 from DKK 1030 * Danske Bank DANSKE.CO : HSBC cuts target price to DKK 231 from DKK 238 * Hermes HRMS.PA : Jefferies initiates coverage with buy rating; price target EUR 2,650 * Rathbone
3
A
A
A
B
B
B
B
B
C
C
C
C
D
F
G
G
H
I
K
L
M
P
P
R
S
S
S
T
V
W
Z
A
D
S
S

Italy's Recordati CEO: shareholder CVC committed to company long-term growth

BRIEF-Italy's Recordati CEO: shareholder CVC committed to company long-term growth May 9 (Reuters) - Recordati CEO Rob Koremans tells analysts: CVC, AS A SHAREHOLDER, IS VERY COMMITTED TO THE COMPANY'S LONG-TERM GROWTH M&A IS AN IMPORTANT PART OF OUR STRATEGY, VERY HAPPY IF THE NEXT DEAL COULD BE IN RARE DESEASE BUSINESS Further company coverage: R
R

Italy's Recordati confirms guidance after robust Q1 performance

Italy's Recordati confirms guidance after robust Q1 performance May 9 (Reuters) - Italian drug maker Recordati RECI.MI posted a 10.5% rise in its first-quarter core profit on Thursday and confirmed its guidance for 2024 and 2025. The company said it had seen a "robust performance... across all key geographies and products". Interest, taxes, depreciation and amortisation (EBITDA) rose to 244.0 million euros ($262 million) with a margin of 40.2% for the January-March quarter, the Milan-based compa
R

Recordati Q1 EBITDA Up To EUR 244.0 Mln

BRIEF-Recordati Q1 EBITDA Up To EUR 244.0 Mln May 9 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : Q1 EBITDA EUR 244.0 MILLION VERSUS EUR 220.8 MILLION YEAR AGO CONFIRMS GUIDANCE FOR 2024 AND 2025 Q1 ADJUSTED NET PROFIT EUR 163.7 MILLION VERSUS EUR 155.0 MILLION YEAR AGO Further company coverage: RECI.MI Reporting by Gdansk Ne
R

Italy - Factors to watch on May 9

Italy - Factors to watch on May 9 The following factors could affect Italian markets on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . DEBT Treasury sells 7.5 billion euros 12-month BOT bills. Subscriptions close at 0900 GMT.
A
B
E
I
I
L
L
P
R
S
S
T
U
A
B
B
B
B
D
F
P
T
I
U

CVC picks banks to explore options for Italy's pharma group Recordati - sources

CVC picks banks to explore options for Italy's pharma group Recordati - sources MILAN, May 8 (Reuters) - CVC Capital Partners has hired JP Morgan and Goldman Sachs to explore options for Italian pharmaceutical group Recordati RECI.MI , two sources close to the matter said on Wednesday. The private equity firm, which owns a majority stake in Recordati, is considering all options, including a sale, a merger with another healthcare company or the creation of a so-called continuation fund, the sourc
G
R

Italy - Factors to watch on May 7

Italy - Factors to watch on May 7 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Italy's rightwing coalition on Monday passed rules curbing the installation of solar panels on agricultural land , ministers said, in a move that triggered criticism as it could undermine Rome's decarbonisati
F
I
L
L
R
S
U
A
A
B
M
T
I
U



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.